DDrare: Database of Drug Development for Rare Diseases

Searched query = "Generalised pustular psoriasis", "Pustular psoriasis", "Herpetic impetigo", "Generalization of acrodermatitis continua", "Generalization of dermatitis continua of the extremities"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AIN457; AIN457, 150mg; ANAKINRA; ANB019; Acitretin; Adalimumab; Alefacept; Alvarez 2; Anakinra; Anti-IL-36R monoclonal antibody; BI 655130; BI655130; Brodalumab; Brodalumab 210mg SC; CNTO1959; Calcitriol; Certolizumab Pegol; Certolizumab pegol; Efalizumab; GUSELKUMAB; Guselkumab; Guselkumab 100 mg; Infliximab; Infliximab [infliximab biosimilar 3]; Ixekizumab; KHK4827; KHK4827 140mg SC; KHK4827 210mg SC; LY3074828; MONOCLONAL ANTIBODY ANTI-IGG1; Mirikizumab; Null; P32; P32/98; P32/98 3%; Placebo; Raptiva; Risankizumab; SECUKINUMAB; Secukinumab; Secukinumab 150 mg/1 mL Solution for injection; Secukinumab 150mg; Secukinumab 300mg; Silikis 3µg/g Salbe; Spesolimab; TA-650; TG; TREMFYA®; Tremfya; Ustekinumab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03885089 (ClinicalTrials.gov)	October 21, 2019	4/3/2019	Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Psoriasis)	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis)	Psoriasis Vulgaris;Psoriasis Arthropathica;Pustular Psoriasis;Erythrodermic Psoriasis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer	NULL	Recruiting	N/A	N/A	All	100		Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03885089
(ClinicalTrials.gov)

October 21, 2019

4/3/2019

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Psoriasis)

Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis)

Psoriasis Vulgaris;Psoriasis Arthropathica;Pustular Psoriasis;Erythrodermic Psoriasis

Drug: Infliximab [infliximab biosimilar 3]

Pfizer

NULL

Recruiting

N/A

All

100

Japan